GlaxoSmithKline Announces Replacement As Director Is Forced To Resign For New Position

GlaxoSmithKline has announced the resignation of one of its Non-Executive Director, Basel Nizameddin. Nizameddin resigned from his position in the company's Board. Oussama Abbas has been appointed as Nizameddin's replacement in the board of the company.

In a statement released by GlaxoSmithKline, Nizameddin resigned from the Board of the Company with effect from July 29, 2020. His resignation "was necessary to enable him attend to other new assignments within the GSK Group." Abbas took over the position from July 29, 2020.

What You Need To Know About Abbas

While commenting on Abbas' appointment, GlaxoSmithKline said, "Mr. Abbas currently Head of Supply Chain – Turkey, Middle East & Africa (MEA), Consumer Health Supply Chain (CHSC), is an accomplished industrial senior executive of GSK with proven abilities in international pharmaceutical, biotech and animal healthcare.

[READ ALSO: GTBank Accused Of Using Customer's Money To Play Bet, As Customers Lose About N770,000]

"He also has solid experience in leading manufacturing plants of commercial and clinical supply-chain operations. He is deeply involved in  corporate organizational changes with understanding of impact on other business functions.

"Abbas has an International Executive MBA (High Distinction) from the Louvain School of Management – Belgium (1999); Doctorate Degree, Faculty of Pharmacy – University Claude Bernard (Lyon –France); Second Degree Master – Focus in Galenic (Formulation –Process –Production) – University Diploma of Pharmaceutical Management, Institut de la Pharmacie Industrielle de Lyon.

"He joined GSK as Director, Secondary Manufacturability& Clinical Supply in May 2009 and has grown through the system to his current position as the Headof Supply Chain of MEA.

"The Board is very confident that with his background, relevant experience and significant involvement in the Global Supply Chain network, Mr. Oussama Abbas would add significant value to the quality and diversity of the Board of GlaxoSmithKline Consumer Nigeria Plc." The company disclosed in the statement seen by AllNews.